Description

Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors[1][2].—Neuroscience-Neuromodulation–C86H116N16O12S4—-[1]Halem HA, et al. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.|[2]Cuny T, et al. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary. 2021 Jun;24(3):351-358.–778630-77-6–1694.20—-CCCN1[C@@]2([H])[C@@](C[C@H](C1)CSCC(N[C@H](CCCCNC(CSC[C@@H]3C[C@]4([H])C5=CC=CC6=C5C(C[C@@]4([H])N(C3)CCC)=CN6)=O)C(N[C@@H]7C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC7)C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CC)=O)CCCCN)=O)CC8=CNC9=CC=CC=C89)=O)CC=CC=C(C=C)O)=O)=O)=O)([H])C=CC=CC=CC(C2)=CN–Neurological Disease; Cancer–10 mM in DMSO–Dopamine Receptor;Somatostatin Receptor–SSTR2–GPCR/G Protein;Neuronal Signaling–Peptides